JACC CardioOncology, Год журнала: 2024, Номер 6(5), С. 631 - 654
Опубликована: Сен. 24, 2024
Язык: Английский
Процитировано
12Risk Assessment Prior to Cardiotoxic Anticancer Therapies in 7 Steps
British Journal of Hospital Medicine, Год журнала: 2025, Номер unknown, С. 1 - 21
Опубликована: Янв. 24, 2025
The burdens of cardiovascular (CV) diseases and cardiotoxic side effects cancer treatment in oncology patients are increasing parallel. European Society Cardiology (ESC) 2022 Cardio-Oncology guidelines recommend the use standardized risk stratification tools to determine cardiotoxicity associated with different anticancer modalities severity their complications. Heart Failure Association-International (HFA-ICOS) is essential for assessing prior starting treatment, validation these methods has been performed receiving anthracyclines, human epidermal receptor 2 (HER2)-targeted therapies breakpoint cluster region-abelson oncogene locus (BCR-ABL) inhibitors. benefits performing baseline CV assessment include early recognition cardiotoxicities, personalisation monitoring strategies, allocation cardioprotection those at highest risk. This review summarizes key points patients. steps identifying target population, nonmodifiable modifiable factors, reviewing previous oncologic histories, investigations. In summary, this aims provide general physicians a simple 7-step guide that will help steer navigate them through cardiac evaluation potentially strategies.
Язык: Английский
Процитировано
1Cardio-oncology: chances and challenges
Basic Research in Cardiology, Год журнала: 2024, Номер unknown
Опубликована: Сен. 30, 2024
Язык: Английский
Процитировано
6Cardiovascular Safety Profile of BRAF and MEK Inhibitors in Melanoma: FAERS Data Through a Retrospective Disproportionality Analysis (2014–2023)
Cancers, Год журнала: 2025, Номер 17(11), С. 1755 - 1755
Опубликована: Май 23, 2025
Introduction: The combination of BRAF and MEK inhibitors (BRAF/MEKi) has significantly improved survival in melanoma patients with V600 mutations. However, these agents can cause cardiovascular (CV) toxicity, compromising efficacy. This study evaluated the CV adverse events (cAEs) associated BRAF/MEKi using U.S. FDA Adverse Event Reporting System (FAERS) to identify new signals disproportionate reporting (SDRs). Methods: Descriptive disproportionality analyses were conducted on reports listing dabrafenib (D), vemurafenib (V), encorafenib (E), trametinib (T), cobimetinib (C), or binimetinib (B) as suspects monotherapy therapy (D + T, V C, E B), indication at least one cAE. Standardized MedDRA Queries (SMQs) related cAEs, including bradyarrhythmias tachyarrhythmias, cardiac failure, cardiomyopathy, thrombotic events, ischaemic heart disease, myocarditis/pericarditis, analyzed. Results: Of 14,077,067 retrieved, 18,370 (0.1%) linked BRAF/MEKi, 1591 (8.7%) primarily (n = 1268). Disproportionality analysis identified 64 clinically relevant SDRs, most which unexpected. Notable findings included bradyarrhythmias, such QT prolongation D T 59; Odds Ratio, ROR 5.09, 95% Confidence Interval, CI 3.94–6.58), failure C (29; 3.76, 2.6–5.42), particularly atrial fibrillation (99; 2.37, 1.94–2.89). Among embolic significant SDRs observed for disseminated intravascular coagulation (38; 10.22, 7.42–14.06) pulmonary embolism (22; 2.79, 1.83–4.24). Conclusions: Our underscore need comprehensive monitoring receiving prevent detect cAEs early reduce treatment-related risks, high-risk populations.
Язык: Английский
Процитировано
0Trends of all-cause, melanoma-specific, and cardiovascular mortality in melanoma patients from 2005 to 2020
Cancer Epidemiology, Год журнала: 2025, Номер 97, С. 102848 - 102848
Опубликована: Май 16, 2025
Язык: Английский
Процитировано
0Cardiac Dysfunction in Children and Young Adults Treated With MEK Inhibitors
JACC CardioOncology, Год журнала: 2024, Номер unknown
Опубликована: Авг. 1, 2024
Язык: Английский
Процитировано
2Navigating cardiotoxicity risk in cancer therapy: the importance of the HFA-ICOS score
European Heart Journal, Год журнала: 2024, Номер unknown
Опубликована: Дек. 16, 2024
Graphical AbstractValidation of HFA-ICOS tool: current evidence and future directions.Open in new tabDownload slide
Язык: Английский
Процитировано
2Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib
Cancers, Год журнала: 2024, Номер 16(17), С. 2945 - 2945
Опубликована: Авг. 23, 2024
Modern therapies targeting the BRAF gene mutation in advanced melanoma have significantly improved patient outcomes but pose cardiovascular risks. This retrospective study Eastern Denmark (2019–2022) assessed 108 patients treated with encorafenib and binimetinib. Patients were monitored for heart function using multigated acquisition (MUGA) scans. The defined major cardiotoxicity as a decline left ventricular ejection fraction (LVEF) by more than 10 percentage points to below 50%, minor decrease LVEF 15 remaining above 50%. Results showed that 19 (18%) developed asymptomatic, while 7 (6%) experienced cardiotoxicity, two requiring intervention. Notably, no significant declines observed after six months of treatment. concluded occurred 6% cases, mostly asymptomatic reversible, suggests monitoring could potentially be reduced 6–9 if early signs are detected. provides valuable insights into cardiac safety these treatments real-world settings.
Язык: Английский
Процитировано
1Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category
JACC CardioOncology, Год журнала: 2023, Номер 5(6), С. 848 - 849
Опубликована: Дек. 1, 2023
Язык: Английский
Процитировано
2New Cardiotoxicity Risk Assessment Guidelines
JACC CardioOncology, Год журнала: 2023, Номер 5(5), С. 638 - 640
Опубликована: Окт. 1, 2023
Язык: Английский
Процитировано
1